Patient Selection: Who Benefits from Oral Versus Injectable GLP-1 Formulations The introduction of oral tablets doesn't render injectable formulations obsolete-rather, it expands the treatment toolkit, allowing physicians to match administration routes to individual patient characteristics, preferences, and circumstances
Semaglutide GLP-1 also slows down how quickly your stomach empties, allowing you to feel fuller for longer and thus diminishing your overall caloric intake
In comparison, the STEP-1 trial reported that 2.4mg/weekly semaglutide led to side effects in 89.7% of the subjects, with the most common complaints being [17]: Nausea (44.2% of subjects) Diarrhea (31.5%) Vomiting (24.8%) Constipation (23.4%) Dyspepsia (10.3%) Abdominal pain (10% Gallbladder-related events (2.6%) The majority of gastrointestinal reactions were of mild to moderate intensity, temporary, and resolved without needing a permanent halt in treatment
It does this through a basic redox reaction, thus protecting cells, DNA, and extracellular matrix components from the damage done by free radicals
Cover Image Credit: Melnyk58 / 123RF.com (Licensed)
People lose around 56 pounds after three months on oral semaglutide (Rybelsus) and up to 14 pounds in three months and 13.6% of their body weight after 15 months on higher doses (Wegovy pill)